Form 4 for AVTX Avalo Therapeutics, Inc.
Accepted 2024-11-14 00:00:00 ET · period of report 2024-11-12 · accession 0001578563-24-000441 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2024-11-14 | 2024-11-12+ | AVTX | Almenoff June Sherie | Dir | P - Purchase | $12.75 | +1,000 | 1,000 | New | +$12.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-12 | P | A | 500 | $12.50 | 500 | I By Meadowlark Management, LLC | — | — | (F1) This transaction was executed in multiple trades ranging from $12.00 to $12.50. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder full information regarding the number of shares and prices at which the transactions were effected. (F2) The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein. |
| 2 | Common | Common Stock | 2024-11-13 | P | A | 500 | $13.00 | 1,000 | I By Meadowlark Management, LLC | — | — | (F2) The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein. |